These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 23133854)
1. Heart benefit of 'good' cholesterol depends on how it occurs. Mayo Clin Health Lett; 2012 Oct; 30(10):4. PubMed ID: 23133854 [No Abstract] [Full Text] [Related]
2. Exercise, C-reactive protein, and your heart. Harv Mens Health Watch; 2005 Jul; 9(12):1-4. PubMed ID: 16161240 [No Abstract] [Full Text] [Related]
3. Mechanisms of disease: HDL metabolism as a target for novel therapies. Rader DJ Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404 [TBL] [Abstract][Full Text] [Related]
7. Nicotinic acid and the prevention of coronary artery disease. Digby JE; Lee JM; Choudhury RP Curr Opin Lipidol; 2009 Aug; 20(4):321-6. PubMed ID: 19494772 [TBL] [Abstract][Full Text] [Related]
8. Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors? Brinton EA; Nanjee MN; Hopkins PN J Am Coll Cardiol; 2004 Jun; 43(12):2233-5. PubMed ID: 15193685 [No Abstract] [Full Text] [Related]
9. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. Parhofer KG Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973 [TBL] [Abstract][Full Text] [Related]
10. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227 [TBL] [Abstract][Full Text] [Related]
11. Rationale for aggressive lipid lowering: evidence from clinical trials. Farmer JA Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477 [No Abstract] [Full Text] [Related]
12. High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events. Fonarow GC; Watson KE Am Heart J; 2004 Jun; 147(6):939-41. PubMed ID: 15199335 [No Abstract] [Full Text] [Related]
13. Diagnosis and management of lipid disorders in children. Rocchini AP Heart Dis Stroke; 1994; 3(5):247-54. PubMed ID: 7820340 [No Abstract] [Full Text] [Related]
14. Hyperlipidemia and cardiovascular disease: should we abandon HDL cholesterol as a therapeutic target in coronary heart disease. Nofer JR Curr Opin Lipidol; 2010 Aug; 21(4):392-3. PubMed ID: 20625261 [No Abstract] [Full Text] [Related]
15. Anti-oxidants and coronary heart disease. Ubbink JB; Vermaak WJ S Afr Med J; 1995 Dec; 85(12):1279-81. PubMed ID: 8600584 [No Abstract] [Full Text] [Related]
17. Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL. Shah PK Nat Rev Cardiol; 2011 Apr; 8(4):187-8. PubMed ID: 21364534 [No Abstract] [Full Text] [Related]
18. Novel insights on high-density lipoprotein in coronary heart disease. Genest J Int J Clin Pract Suppl; 2002 Oct; (132):17-22. PubMed ID: 12425359 [No Abstract] [Full Text] [Related]
19. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol]. Carlson LA Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660 [No Abstract] [Full Text] [Related]
20. Focus on HDL as a therapeutic target for CAD risk reduction. Davidson MH Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937 [No Abstract] [Full Text] [Related] [Next] [New Search]